Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.

Content Provider	Europe PMC
Author	Joshi, Smita Anantharaman, Devasena Muwonge, Richard Bhatla, Neerja Panicker, Gitika Butt, Julia Rani Reddy Poli, Usha Malvi, Sylla G. Esmy, Pulikkottil O. Lucas, Eric Verma, Yogesh Shah, Anand Zomawia, Eric Pimple, Sharmila Jayant, Kasturi Hingmire, Sanjay Chiwate, Aruna Divate, Uma Vashist, Shachi Mishra, Gauravi Jadhav, Radhika Siddiqi, Maqsood Sankaran, Subha Pillai Rameshwari Ammal Kannan, Thiraviam Kartha, Purnima Shastri, Surendra S. Sauvaget, Catherine Radhakrishna Pillai, M. Waterboer, Tim Müller, Martin Sehr, Peter Unger, Elizabeth R. Sankaranarayanan, Rengaswamy Basu, Partha
Copyright Year	2022
Abstract	BackgroundThe recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10 years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women.MethodsParticipants received at age 10–18 years either one, two or three doses of the quadrivalent HPV vaccine. Serology samples were obtained at different timepoints up to 10 years after vaccination from a convenience sample of vaccinated participants and from age-matched unvaccinated women at one timepoint. The evolution of the binding and neutralizing antibody response was presented by dose received. 10-year durability of immune responses induced by a single-dose was compared to that after three doses of the vaccine and in unvaccinated married women.ResultsThe dynamics of antibody response among the single-dose recipients observed over 120 months show stabilized levels 18 months after vaccination for all four HPV types. Although the HPV type-specific (binding or neutralizing) antibody titres after a single-dose were significantly inferior to those after three doses of the vaccine (lower bounds of GMT ratios < 0.5), they were all significantly higher than those observed in unvaccinated women following natural infections (GMT ratios: 2.05 to 4.04-fold higher). The results correlate well with the high vaccine efficacy of single-dose against persistent HPV 16/18 infections reported by us earlier at 10-years post-vaccination.ConclusionOur study demonstrates the high and durable immune response in single-dose recipients of HPV vaccine at 10-years post vaccination.
ISSN	0264410X
Journal	Vaccine
Volume Number	41
PubMed Central reference number	PMC9792650
Issue Number	1
PubMed reference number	36446654
e-ISSN	18732518
DOI	10.1016/j.vaccine.2022.11.044
Language	English
Publisher	Elsevier Science
Publisher Date	2022-11-26
Access Restriction	Open
Rights License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2022 The Author(s)
Subject Keyword	Human papillomavirus quadrivalent HPV vaccine Single dose Vaccine immune responses Natural immunity HPV, Human papillomavirus
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases Immunology and Microbiology Veterinary Public Health, Environmental and Occupational Health Molecular Medicine